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Abstract
Hereditary angioedema (HAE) is a rare genetic disorder, 
characterized by recurrent and unexpected potentially  
life-threatening mucosal swelling. The impairment 
underlying HAE could be a defect in C1-inhibitor activity,  
or in its serum concentration. Patients affected by HAE 
should be treated with on-demand or prophylactic drugs. 
Lifelong C1-inhibitor supplementation is sometimes required. 
In this review, we review the currently approved drugs for 
HAE due to C1-inhibitor defect and to describe those under 
research. In particular, we focused on the mechanisms of 
action, routes of administration, and efficacy of these therapies. 
A systematic review of the literature was performed using 
the PubMed database for original articles and clinical trials 
of HAE treatments from 2005 to 2019. The approved HAE 
treatments can minimize the risk of death, but they are not 
effective in complete healing from the disease. The new gene 
therapies seem to provide promising opportunities for the 
treatment of hereditary angioedema. However, there are still 
many unmet needs, including efficacy, route, and timing of 
administration.
Keywords: C1-INH, C1-inhibitor, gene therapy, HAE, 
hereditary angioedema, lanadelumab, serine protease, 
SERPING1.
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Introduction
Hereditary angioedema (HAE), in its two main forms (types I 
and II), is due to the lack or dysfunction in the C1-inhibitor  
(C1-INH). However, in other phenotypes of HAE, C1-INH levels 
are normal, and the disease is called ‘hereditary angioedema 
with normal C1-INH.’ This effect is associated with specific 
genetic mutations: HAE caused by FXII gene mutations 
(HAE-FXII),1 hereditary angioedema due to mutations in the 
plasminogen gene (HAE-PLG),2 and HAE associated with 
angiopoietin-1 gene mutations (HAE-ANGPTI).3
The clinical features of HAE are recurrent and unpredictable 
spontaneous edema attacks. Traumas, infections, stress, 
or medical procedures are potential triggers for HAE 
attacks, although they are not always so clearly detectable. 
Occasionally, angioedema could be associated with prodromal 
signs, including erythema marginatum.4–6
Most mild angioedema attacks involve lips, eyelids, or 
peripheral limbs, and these attacks are self-limiting and rarely 
harmful. In this case, swelling arises slowly, lasting 2–5 days, and 
then progressively disappearing, even without therapy.
However, in cases of larynx, tongue, or abdomen involvement, 
HAE attacks could potentially be life-threatening. The most 
serious and feared complication of a larynx HAE attack is 
choking due to the swelling and thickness of vocal cords. In 
addition, bowel angioedema attacks may occur as nausea, 
vomiting, or abdominal pain due to intestinal wall edema. 
These could mimic other diseases, such as acute appendicitis 
or a surgical abdomen, thus increasing the likelihood of 
misdiagnosis and unnecessary surgery.7
The dysregulation of bradykinin pathways is responsible for 
angioedema attack onset. Bradykinin is, in fact, generated 
by the kallikrein-kinin system, and it usually binds to the 
bradykinin B2 receptors on endothelial cells. The C1-INH is a 
serine protease, the primary role of which is protease inhibition, 
including kallikrein.8 In the case of C1-INH dysfunction or 
deficiency, bradykinin production is not inhibited, with 
consequent vascular permeability increase and angioedema 
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swelling.9 The C1-INH protein is encoded by the serpin 
peptidase inhibitor clade G member 1 (SERPING1) gene on 
chromosome 11q12-q13.1.10
Due to the rarity of the disease and frequent misdiagnosis 
(i.e., histamine-mediated angioedema, angiotensin-
converting enzyme inhibitor angioedema, etc.),11 the delay 
in HAE diagnosis could be up to 20 years.12 This delay causes 
a significant economic and psychological burden for both 
healthcare associations and affected patients.13
The proper and quick identification of the disease is 
increasingly important, as the treatment of the attacks and 
their prevention is possible due to the currently available drugs. 
These drugs can, in fact, improve the patient quality of life by 
reducing the number and severity of HAE attacks.
Many different approaches for HAE treatment are now 
available, and many are in the pipeline. This review aims to 
provide an overview of the newly approved drugs for HAE 
treatment in Europe, focusing on new approaches, including 
biologics and gene therapies.
Materials and methods
Database and key words (MeSH)
A systematic review of the literature was performed, according 
to the PRISMA statement, by using the PubMed database 
for original articles and clinical trials of HAE treatments from 
January 2005 to August 2019 (Figure 1).
The following keywords alone and/or in combination were 
used: ‘Hereditary angioedema treatment,’ ‘HAE and C1-
INH management,’ ‘HAE and FXII management,’ ‘HAE and 
treatment,’ ‘HAE and biologics,’ ‘HAE and gene therapy,’ ‘HAE 
and molecular approach,’ ‘HAE and trials,’ ‘HAE and new 
therapies,’ and ‘HAE and management.’
In addition, reports coming from the website  
https://clinicaltrials.gov were evaluated, as well as notes 
released by the European Medicine Agency (EMA) and the Food 
and Drug Administration (FDA) concerning HAE treatment 
withdrawal or approval.
Figure 1. PRISMA 2009 Flow Diagram. 
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Selection criteria
We selected original articles and reviews assessing HAE-
approved treatment and papers presenting preliminary data 
of phase 1, phase 2, or phase 3 clinical trials. In one case, we 
analyzed an ex vivo preliminary study on nonhuman primates.14
Data collection
Two researchers identified and selected the full-text papers. 
The selection was blind and completely independent of 
the two people. Discrepancies of the selected articles were 
resolved by consensus.
Therapeutic approved strategies 
for the management of HAE
Three different approaches are now available for HAE 
treatment, according to the frequency and severity of attacks. 
Over the last few decades, FDA and EMA have approved new 
safe and effective drugs for hereditary angioedema treatment 
(Figure 2) (Table 1). 
Most recent drugs (Tables 2 and 3) can improve therapeutic 
efficacy, presenting fewer adverse events than the oldest drugs. 
The high frequency of virilization and liver impairment caused 
by androgens and the infectious risk related to frozen plasma 
administration are widely known.15
Patients can now be treated either with an on-demand 
therapy, which is administered immediately after the onset of 
swelling, or they might receive a short-term prophylaxis, used 
to prevent HAE attacks related to high-risk procedures (e.g., 
surgical or dental practices). A third option could be long-term 
prophylaxis, indicated in patients who cannot achieve disease 
control from on-demand treatment alone. The primary purpose 
of long-term prophylaxis is to decrease the overall number and 
severity of HAE attacks.16,17
On-demand therapy
Traditional approved drugs
Berinert®
In 2009, the FDA approved Berinert® (CSL Behring), a pasteurized 
plasma-derived C1-INH concentrate, available for intravenous 
(IV) administration in patients needing on-demand therapy. 
This drug was not approved for short-term prophylaxis but is 
used off-label for this purpose. A randomized, double-blind, 
placebo-controlled (DBPC) study in 125 patients affected by 
type I or type II HAE, Berinert®, at a dose of 20 U/kg, showed a 
significant reduction in the time to the relief of HAE symptom 
onset (30 versus 90 minutes; p=0.003) and a shortening in time to 
complete symptom resolution (294 versus 468 minutes; p=0.02) 
compared with the placebo.18 The proper dose of Berinert® for an 
HAE attack is 20 U/kg IV given at 4 mL/min. In terms of safety, no 
seroconversions were observed for HIV, hepatitis virus, or human 
B19 virus during the approval studies or in real-life experiences.19
Cinryze®
A second intravenously administered plasma-derived C1-INH 
concentrate, with the marketing name Cinryze® (Shire), has 
Figure 2. Site of action of current and under research therapies for HAE 
treatment.
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recombinant C1 inhibitor (Ruconest®, Pharming Healthcare) for 
on-demand treatment of HAE attacks in adolescents (≥12 years) 
and adults. The active ingredient in Ruconest® is conestat alfa, 
which is a glycoprotein similar to the human  
C1-INH produced by recombinant DNA technology in a  
transgenic species of rabbits called New Zealand White (NZW) 
and then purified from their milk. Its amino acid sequence is an 
analogue of endogenous human C1 inhibitor, having a shorter 
half-life due to a different glycosylation pattern.24,25 In a pooled 
analysis of two different studies comparing conestat alfa with 
placebo, Zuraw and his research group reported a significantly 
shorter time in the beginning of symptom relief in the  
conestat alfa group. The median time in minutes was 66 minutes  
(Ruconest® 100 U/kg), 122 minutes (Ruconest® 50 U/kg) and  
495 minutes (saline), p<0.001 and p=0.013, respectively, referred 
to each dose compared with placebo (saline).26 Because of the 
potential of rabbit protein in the preparation, Ruconest® is  
contraindicated in patients with a history or a suspicion of 
rabbit hypersensitivity.24
Long-term prophylaxis
Long-term prophylaxis should be considered in symptomatic 
patients despite an optimized on-demand treatment of 
angioedema attacks. In addition, the frequency of attacks, 
disease activity level, and patient quality of life should be taken 
into consideration.16 
been approved by EMA for on-demand HAE attack treatment, 
short-term and long-term prophylaxis (see later).20
Firazyr®
Icatibant (Firazyr®, Shire) is a bradykinin B2 receptor antagonist 
approved by EMA in 2008 as an on-demand treatment for 
HAE attacks in adult patients. In a randomized, double-blind, 
placebo-controlled study, icatibant significantly reduced the 
median time in symptom severity reduction (120 versus 1188 
minutes; p=0.001) and the onset of symptom relief (90 versus 
1110 minutes; p=0.001) compared with the placebo.21 Icatibant 
is given as a subcutaneous injection of 30 mg (in 3 mL), 
repeatable after 6 hours (at most three injections in 24 hours).22
Kalbitor®
Ecallantide (Kalbitor®, Shire) is a potent kallikrein inhibitor 
approved by the FDA for the treatment of HAE attacks 
in patients aged ≥12 years, administered as a 30-mg 
subcutaneous dose. However, this drug was withdrawn in 
November 2011 because of the Committee for Medicinal 
Products for Human Use (CHMP) opinion, as the benefits of 
Kalbitor® did not outweigh its risks.23
Biologic approved drugs
Ruconest®
To reduce the potential risk of blood-borne infections due 
to plasma-derived C1-INH, in 2010, the EMA approved a new 
Table 1. Approved treatment options for C1-INH HAE.
Drug name Active 
substance
Type and action Administration Indication T1/2
Kalbitor®, Dyax Corp Ecallantide Kallikrein inhibitor SC On-demand 
treatment
2 hours
Firazyr®, Shire Icatibant Bradykinin B2 receptor 
antagonist
SC On-demand 
treatment
2–4 hours
Ruconest®, Pharming Conestat alfa Recombinant C1 inhibitor 
from milk of transgenic 
rabbits
IV On-demand 
treatment
3 hours
Berinert®, CSL Behring C1-INH Plasma-derived C1-INH 
concentrate pasteurized
IV On-demand 
treatment,
Short-term 
prophylaxis
36–48 hours
Cinryze®, Shire C1-INH Plasma-derived  
C1-INH concentrate 
nanofiltered
IV Long-term 
prophylaxis
36–48 hours
Haegarda®, CSL Behring C1-INH Human plasma-derived 
concentrate of C1 
esterase inhibitor
SC, IV Long-term 
prophylaxis
69 hours (SC), 
56 hours (IV)
Takhzyro®, Shire Lanadelumab Recombinant, fully 
human IgG1 monoclonal 
antibody inhibitor of 
kallikrein
SC Long-term 
prophylaxis
14 days
C1-INH, C1-inhibitor; HAE, hereditary angioedema; IV, intravenous; SC, subcutaneous.
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The available treatments can be divided into two main groups: 
traditional approved drugs and new biologics. The former 
includes C1-nanofiltered inhibitor, widely described later, and 
attenuated androgens or antifibrinolytics, which, although 
commonly used in clinical practice, are not the purpose of this 
review. Among the new emerging biologics, lanadelumab is the 
first and the only biologic that has been approved by the EMA.
Traditional approved drugs
Cinryze®
In 2011, the EMA approved a new plasma-derived C1 inhibitor 
concentrate nanofiltered (Cinryze®, Shire) for HAE management 
in adults. In 2016, the drug was also approved for treatment 
and pre-procedure prevention of HAE attacks in children from 2 
years and as a routine prevention of angioedema attacks from 
6 years.20 Cinryze® is indicated as on-demand therapy, with a 
starting dose of 1000 Units IV as HAE arises, repeatable after 
1 hour. In addition, the drug could be administered for short-
term prevention of angioedema attacks, by giving 1000 U IV 
within 24 hours before the procedure. A third approved option 
is, finally, to use it as long-term prophylaxis, at the dose of 1000 
U IV of Cinryze® every 3 or 4 days.20
A randomized double-blind, placebo-controlled 12-week 
trial showed a significant reduction in the frequency of HAE 
in patients treated with twice weekly injections of 1000 U of 
Cinryze® versus placebo (6.3 attacks in the Cinryze® group versus 
12.7 attacks in the placebo group; p<0.001).27
After marketing, several thrombotic events, thought to be 
secondary to the use of indwelling catheters rather than the 
drug, were reported, leading to a recommendation to avoid 
indwelling catheters for IV C1-INH prophylaxis.28
Haegarda®
Haegarda® (CSL Behring) was approved by the FDA in 2017 as 
the first subcutaneous C1 inhibitor concentrate, also indicated 
for self-administration, at the dose of 60 IU/kg twice weekly. 
Nevertheless, the European Medicines Agency did not formally 
approve the marketing of the drug.29 
Biologic approved drugs
Takhzyro®
Lanadelumab (SHP643; previously DX-2930) is a fully human 
IgG1 monoclonal antibody that selectively inhibits plasma 
kallikrein,18 marketed by Takeda with the name Takhzyro®. 
This agent was approved in October 2015 by the EMA30 as an 
orphan drug for prophylaxis in HAE attack prevention, available 
Table 2. Ongoing trials for C1-INH HAE treatments (from the EU Clinical Trials Register website).
Drug name Active substance Type and action Administration Indication T 1/2
BCX7353®, BioCryst 
Pharmaceuticals53
R)-1-(3-(aminomethyl)
phenyl)-N-(5-((3-cyanophenyl)
(cyclopropylmethylamino)
methyl)-2-fluorophenyl)-
3-(trifluoromethyl)-1H-
pyrazole-5-carboxamide 
dihydrochloride
Second-generation 
oral kallikrein 
inhibitor
PO Long-term 
prophylaxis
50–60 
hours
Berinert®, CSL 
Behring54
C1-INH Plasma-derived 
C1-INH concentrate 
pasteurized
SC Long-term 
prophylaxis
120
C1-INH, C1-inhibitor; HAE, hereditary angioedema; PO, orally administered; SC, subcutaneous.
Table 3. Treatments for C1-INH HAE under 
research.
Drug product Type
Gene therapy to correct 
C1 inhibitor deficiency55
Delivering an 
extrachromosomal copy 
of SERPING1 by using an 
adeno-associated virus 
vector.
ALN-F12®, Alnylam56 Inhibiting factor XII by using 
RNA interference to reduce 
its expression.
CSL312®, CSL Behring45 Phase I trial for a human 
monoclonal antibody 
against factor 12.
KVD900®, KalVista 
pharmaceutical51
Phase I trial for an on-
demand orally administered 
plasma kallikrein inhibitor.
IONIS-PKK®, Ionis 
Pharmaceuticals47
Completed phase I 
trial for an antisense 
oligonucleotide to 
reduce the production of 
prekallikrein.
ATN-249®, Attune 
Pharmaceuticals57
Preclinical studies on 
monkeys for a new oral 
kallikrein inhibitor.
Avoralstat®, BioCryst 
Pharmaceuticals50
Phase 3 trial for a long-
term prophylaxis orally 
administered small 
kallikrein inhibitor.
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for adult patients and adolescents aged ≥12 years. The half-
life of the drug is indeed ≥2 weeks.31 The recommended dose 
is 300 mg every 2 weeks, which may be extended to every 4 
weeks in well-controlled patients who did not complain of any 
attacks in the last 6 months.31,32 The Hereditary Angioedema 
Long-term Prophylaxis (HELP) Study™ was a multicentric, 
randomized, double-blind, placebo-controlled parallel group 
trial in 125 patients who are 12 years of age or older with 
HAE, over 26 weeks, that evaluated the efficacy and safety of 
subcutaneously administered lanadelumab (at the dose of 150 
mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 
weeks) versus placebo.33 The primary endpoint measured the 
HAE attack incidence over 6 months (26 weeks), whereas the 
secondary endpoints evaluated how many attacks required an 
acute treatment and the number of attacks with severity that 
was moderate or severe. The three aforementioned doses of 
lanadelumab showed a significant superiority compared with 
the placebo for all primary and secondary endpoints (p<0.001 
for all comparisons). No severe treatment-emergent adverse 
events or deaths were reported.33 
Short-term prophylaxis
Short-term prophylaxis is administered with the aim of 
preventing HAE attacks in patients who need to undergo 
invasive procedures potentially acting as a trigger, such as 
dental care, surgery, endoscopic examinations, childbirth, and 
stressful situations.
Although the risk of potentially life-threatening invasive 
procedures is high, no controlled trials compared the efficacy  
of different approaches for short-term prophylaxis.
In 2017, the International World Allergy Organization, in 
cooperation with the European Academy of Allergy and Clinical 
Immunology (WAO/EAACI), released a new update of the 
HAE guidelines. In the revision, WAO/EAACI recommends a 
preprocedural C1-INH concentrate administration in all cases 
of medical, surgical, and dental procedures associated with any 
mechanical impact to the upper aerodigestive tract (Evidence 
grade: C; strength of recommendation: Strong).16 
Nevertheless, HAE attacks can still occur despite proper 
preprocedural prophylaxis. For this reason, all patients should 
stay under medical supervision a few hours following the 
procedure. In addition, on-demand treatment (C1-INH or 
icatibant plasma concentration) should be available in cases 
of unpredictable acute attacks.16 The drugs of choice for this 
approach are C1 INH plasma concentrate.
Novel biologic drugs and gene 
therapies in the pipeline
The new era of gene therapy and monoclonal antibodies 
(mAbs) has led to the development of several new approaches 
for HAE management, which are now being investigated.
The most interesting treatments are gene therapy, which 
aims to restore the lack in C1-INH by administering a new 
extrachromosomal copy of SERPING1 into patient cells by 
using an adeno-associated virus vector, the use of an antisense 
oligonucleotide to reduce prekallikrein production (Ionis-PKK), 
the use of an RNA interference to reduce Factor XII expression 
(ALN-F12, ARC-F12), a human monoclonal antibody against 
Factor XII (CSL312), and a recent kallikrein inhibitor (ATN-249).
The main purpose of these novel approaches is to reduce the 
need for medications and to improve the quality of life of HAE 
patients by modifying the course of the disease.
AAVrh.10hC1EI
Qui and his research group are evaluating in a preclinical study 
the efficacy of gene therapy on C1-INH HAE. They hypothesized 
that C1-INH deficiency could be restored by administering 
an additional extrachromosomal copy of the SERPING1 gene 
into the cells of affected patients using an adeno-associated 
virus vector.34 The authors created a C1-INH-deficient mouse 
model presenting the clinical and molecular phenotype of 
HAE due to a frameshift mutation, which leads to an early stop 
codon in exon 3, and they called it the ‘S63 mouse model.’34 
These authors hypothesized that one injection of a serotype 
rh.10 adeno-associated virus (AAV) vector, which encodes the 
human C1 esterase inhibitor (C1EI) (AAVrh.10hC1EI), is sufficient 
for recovering from the disease. The expression of human C1EI 
would indeed be persistent, and no more HAE manifestations 
will appear. In this study, the authors analyzed the vascular 
permeability in both S63+/− and wild-type control mice with or 
without vector treatment. For the assessment, the authors used 
Evans blue dye and evaluated mouse outcomes after 2, 6, and 
24 weeks from the AAVrh.10C1EI (1011 gc) administration.34
The authors demonstrated that, in both in vivo and in vitro 
assessments and independent of mouse gender, a single 
administration of AAVrh.10hC1EI allowed enough systemic 
production of C1-INH to prevent the vascular permeability 
causing HAE manifestations.
One of the major limits of this study is that the evaluation was 
restricted to 24 weeks, although the authors revealed that 
they have demonstrated long-term expression measured over 
several years.35–37
This study establishes that a gene therapy expressing C1-INH 
helps in HAE healing in a mouse model. Nevertheless, it is 
mandatory that additional toxicology and safety studies assess 
the efficacy and feasibility of this approach in clinical practice, 
focusing on dosing regimens and drug safety.
ARC-F12
ARC-F12™ is a new RNAi-based product developed by 
Arrowhead Pharmaceuticals. It is now under investigation 
for the treatment of diseases due to a dysfunctional Factor 
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XII. Some preclinical studies are ongoing, and ARC-F12™ will 
probably be proposed for future clinical trials.38
ALN-F12
ALN-F12 is an FXII targeting small-interfering RNA (siRNA) 
conjugated with trivalent N-acetylgalactosamine (GalNAc) 
ligand, which was demonstrated to be able to compensate 
for the defect resulting from the loss of functional C1INH due 
to F12 mutations. Liu and coauthors evaluated the efficacy 
of ALN-F12 in mice, rats, and cynomolgus monkeys, as well 
as in an ex vivo assay assessing the relationship between the 
cleavage of high-molecular weight kininogen (HK) and plasma 
levels of human FXII. These authors demonstrated a significant 
dose-dependent decrease in plasma FXII levels in all rats, 
mice, and monkeys, after only one subcutaneous injection of 
ALN-F12. Moreover, an ex vivo human plasma HK cleavage assay 
indicated FXII-dependent bradykinin generation.14
Until recently, no studies for ALN-F12 in vivo human evaluation 
have been developed.
BCX7353
BCX7353, the active substance of which is (R)-1-
(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)
(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-
(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride, 
is a potent, synthetic small molecule demonstrated to be able 
to inhibit plasma kallikrein. The drug was developed for both 
long-term prophylaxis and on-demand treatment.39,40
In 2016, the first-in-human phase 1 trial evaluated single or 
multiple once-daily oral administration of BCX7353 or placebo 
in healthy volunteers. The half-life of BCX7353 was shown to be 
50–60 hours, and the target therapeutic plasma concentrations 
were reached in 7 days, without any AEs reported.41
According to these results, the phase 2 Angioedema 
Prophylaxis 1 (APeX-1) trial39 evaluated BCX7353 in its four dose 
regimens (62.5, 125, 250, and 350 mg, administered once daily) 
for long-term prophylaxis in angioedema attacks over a 4-week 
period and compared them with the placebo. 
The primary efficacy end point was the number of angioedema 
attacks, which was demonstrated to be reduced up to 73.8%. 
Key secondary end points included angioedema attacks 
according to anatomical location and the change from baseline 
in AE-QoL scores. Secondary endpoints also supported the 
efficacy of BCX7353 at doses of 125 mg or more. Three patients 
who received BCX7353 at a dose of 350 mg discontinued the 
trial regimen owing to adverse events, whereas the incidence 
in the 62.5-mg dose group was similar to that in the placebo 
group (18%). 
A second phase 2, double-blind, placebo-controlled, 
randomized, crossover, dose-ranging trial, ZENITH-1, evaluated 
the efficacy of the 750 mg dose of BCX7353 in the treatment of 
three HAE attacks: two treated with active drug and one with 
placebo, in a randomized sequence. 
The results showed that at 4 hours post-dose, 67.7% of HAE 
attacks treated with BCX7353 and 46.7% of those treated with 
placebo were stable or improved (OR=2.771, p=0.0387). The 
evaluation was made by composite VAS, and the results were 
maintained at 24 hours.40
Based on the results of ZENITH-1, the company plans to start 
a phase 3 trial with the 750 mg dose of oral BCX7353 in the 
summer of 2019.42
CSL312
The fully human recombinant antibody 3F7 is a potent and 
highly specific inhibitor of the proteolytic activity of FXIIa that 
specifically binds to the catalytic domain of FXIIa with high 
affinity and completely inhibits its protease activity.43 3F7 was 
initially developed to provide thromboprotection as efficiently 
as heparin without increasing the bleeding risk,44 but it was 
found to be effective also in the reduction of angioedema 
attacks in HAE III mouse models and in bradykinin-mediated 
angioedema induced by captopril in C1-INH-deficient mice,45 
laying the foundations for further studies.
In addition, a variant of 3F7 with improved affinity and potency 
developed by CSL Behring®, called CSL312, has been shown 
to effectively inhibit dextran sulfate-triggered FXII contact 
activation and bradykinin formation in the plasma of healthy 
donors and HAE murine models.45
In October 2018, a multicenter, randomized, placebo-
controlled, parallel-arm, phase 2 study was started to 
investigate the clinical efficacy, pharmacokinetics, and safety  
of CSL312 as prophylaxis to prevent attacks in subjects  
with HAE.46
IONIS-PKKRX
The targeted inhibition of prekallikrein (PKK) expression 
using antisense oligonucleotide (ASO) technology is a novel 
emerging therapeutic approach for hereditary angioedema 
due to genetic deficiencies of PKK or FXII.
IONIS-PKKRx, designed by Ionis Pharmaceutical™, is a 
second-generation 2-O-(2-methoxyethyl)-modified antisense 
oligonucleotide of murine derivation that aims to reduce 
hepatic PKK mRNA by binding prekallikrein. IONIS-PKKRx was 
shown to be dose-dependent effective in reducing human 
prekallikrein mRNA in the liver and PKK protein in the plasma of 
mice expressing the human PKK transgene (hPKK-Tg) and dose- 
and time-dependent reductions of plasma PKK in Cynomolgus 
monkeys, showing a tissue half-life of 20.5–27.7 days.47 
Preliminary trials in healthy human volunteers demonstrated 
that IONIS-PKKRx was able to dose-dependently reduce 
plasma levels of PKK and bradykinin production, with a good 
tolerability and safety profile.
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IONIS-PKKRx was evaluated in a Canadian phase 1 randomized 
DBPC study in healthy volunteers (BioPharma Services, Inc., 
Toronto, Canada) between May 2014 and January 2015. The 
subjects were randomly assigned 3:1 to receive a single 
subcutaneous IONIS-PKKRx injection (50, 100, 200, or 400 mg) 
or placebo.47 The pharmacodynamic effects in healthy human 
volunteers were consistent with the preclinical results.47 
In the 300 and 400 mg cohorts, IONISPKKRx was effective in 
dose-dependent reduction of plasma PKK protein levels and 
bradykinin production after 29 days from injection, sustained 
up to day 113. 
In addition, the finding of a conversion from FXII to the active 
form (FXIIa) is thought to be consistent with the role of PKK/
kallikrein in activation of FXII.47
ATN-249
ATN-249 is a novel, potent, selective, and oral-administered 
plasma kallikrein inhibitor for the treatment of HAE. Preclinical 
studies seemed to support ATN-249 as a highly selective and 
effective kallikrein plasma inhibitor. Upon the conclusion of the 
phase I study in healthy volunteers, a phase 2 trial is expected 
to commence. The aim of this phase 2 study, over a 4-week 
period, would be the assessment of dose ranging, as well as 
the tolerability, safety, pharmacodynamics, pharmacokinetics, 
and efficacy of ATN-249 as a prophylactic treatment in HAE 
patients.48
Avoralstat
Avoralstat (BioCryst Pharmaceuticals, Durham, North Carolina), 
which was previously named BCX4161, is a potent, small 
molecule inhibitor of kallikrein.49
The clinical trial named OPuS-2 (NCT02303626, EudraCT 2014-
002655-26) is a phase 3, multicenter, randomized, double-blind, 
placebo-controlled, parallel-group study aimed to test the 
efficacy of avoralstat in long-term prophylaxis.50
Patients were randomized in a 1:1:1 ratio to receive avoralstat 
500 mg, 300 mg, or placebo, administered orally, three times 
per day for 12 weeks. The primary endpoint was the weekly 
confirmed number of angioedema attacks. Secondary efficacy 
endpoints included the number of attack-free days, the weekly 
subject-reported attack rate, the average attack severity score, 
and the AE-QoL score.50
The primary endpoint was not achieved, with confirmed 
attacks of 0.59, 0.68, and 0.59 for subjects in the three 
treatment arms (p≥0.5). In addition, except for quality of life, no 
other secondary endpoint was achieved.50
KVD900
KVD900 is a potent and selective small molecule plasma 
kallikrein inhibitor developed for the on-demand treatment of 
HAE attacks. A phase 1 single ascending dose study evaluated 
the pharmacodynamics of the drug by testing 8 ascending 
doses from 5 to 600 mg in healthy men. The 600-mg single 
dose provided >90% inhibition of plasma kallikrein catalytic 
activity between 30 minutes and 6 hours post-dose and 
>50% inhibition for 10 hours. The authors suggested that the 
drug could be used as a rapidly acting oral treatment for HAE 
attacks.51 
Conclusion
The severity and timing of HAE attacks are unpredictable, 
mainly due to the lack of a complete understanding of the 
mechanisms underlying the disease onset. In addition, swelling 
without urticaria is the feature of most HAE attacks, regardless 
of the molecular basis. 
The approved treatments can actually avoid or minimize the 
risk of death, but they are not effective in complete healing 
from the disease. Moreover, a personalized approach becomes 
increasingly important to obtain adequate disease control. In the 
recent years, the development of many subcutaneous and oral 
drugs has allowed people to take these medications at home, 
reducing missed work days and healthcare-associated costs.52
More recently, gene therapy approaches seem to provide 
promising opportunities for the treatment of hereditary 
angioedema. 
However, there are still many unmet needs concerning new 
therapies, including efficacy, costs, route, and timing of 
administration. 
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